Morgan Stanley lowered the firm’s price target on Adagene to $4.60 from $5 and keeps an Overweight rating on the shares. The firm lowered its price target based on updated Yervoy U.S. sales projections and PD-1 sales in China while also moving forward its net cash and shares outstanding projections to 2024 from 2023.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ADAG: